Trabecular Bone Score and Osteoprotegerin as Useful Tools in the Assessment of Bone Deterioration in Acromegaly.
BMD
TBS
acromegaly
fracture
osteoporosis
osteoprotegerin
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
01
2022
accepted:
21
03
2022
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
11
5
2022
Statut:
epublish
Résumé
This study aimed to assess bone mineral density (BMD) and trabecular bone score (TBS) in 61 patients from the acromegaly group (AG) with regard to the activity of the disease in comparison to 42 patients-control group (CG). We also analyzed selected bone markers and their association with BMD and TBS. Lumbar spine and femoral neck BMD measurements were performed. TBS values were obtained. Serum concentrations of selected bone markers, including osteoprotegerin (OPG), were measured. We revealed a difference in TBS values between the AG and CG as well as between the TCA (treatment-controlled acromegaly) vs. CG and TCA+CA (cured acromegaly) vs. CG. We did not observe any statistically significant difference in BMD. OPG had a lower concentration in the CG compared to the AG. TBS correlated negatively with OPG in the AG (r = -0.31, p = 0.01) and in the TCA+ CA group (r = -0.3, p = 0.01). The acromegalic patients have altered bone microstructure as indicated by the decreased TBS regardless of the activity of the disease and BMD. OPG could be a marker of the destruction of the bone microstructure, but further studies are needed.
Identifiants
pubmed: 35528019
doi: 10.3389/fendo.2022.862845
pmc: PMC9068997
doi:
Substances chimiques
Osteoprotegerin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
862845Informations de copyright
Copyright © 2022 Jawiarczyk-Przybyłowska, Halupczok-Żyła, Syrycka, Zembska, Kuliczkowska-Płaksej and Bolanowski.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Densitom. 2016 Oct;19(4):544-545
pubmed: 27067300
Bone. 2017 Nov;104:39-43
pubmed: 28041872
Pituitary. 2018 Feb;21(1):56-64
pubmed: 29214508
Endokrynol Pol. 2020;71(6):524-531
pubmed: 32944924
Eur J Endocrinol. 2003 Feb;148(2):185-91
pubmed: 12590637
Eur J Endocrinol. 2006 Nov;155(5):709-15
pubmed: 17062887
Front Endocrinol (Lausanne). 2020 Jun 24;11:418
pubmed: 32670201
Expert Rev Endocrinol Metab. 2015 Mar;10(2):169-176
pubmed: 30293506
Clin Endocrinol (Oxf). 2002 Sep;57(3):385-90
pubmed: 12201832
J Bone Miner Res. 2016 May;31(5):940-8
pubmed: 26498132
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2416-2424
pubmed: 28407138
Bone. 2008 Dec;43(6):1115-21
pubmed: 18793764
Clin Endocrinol (Oxf). 2003 Jun;58(6):725-31
pubmed: 12780749
Clin Endocrinol (Oxf). 2021 Jul;95(1):58-64
pubmed: 33559169
Osteoporos Int. 2016 Mar;27(3):1123-1129
pubmed: 26446771
Nat Rev Endocrinol. 2018 Sep;14(9):552-561
pubmed: 30050156
J Clin Endocrinol Metab. 2008 Dec;93(12):4649-55
pubmed: 18827004
Osteoporos Int. 2013 Nov;24(11):2837-46
pubmed: 23681084
Eur J Endocrinol. 2011 Apr;164(4):475-83
pubmed: 21257726
PLoS One. 2011 Mar 18;6(3):e14762
pubmed: 21445249
J Clin Densitom. 2014 Apr-Jun;17(2):314-9
pubmed: 24582086
Endocr J. 2014;61(3):231-7
pubmed: 24304925
Osteoporos Int. 2002;13(4):303-8
pubmed: 12030545
Endokrynol Pol. 2019;70(4):350-356
pubmed: 31489959
J Clin Densitom. 2013 Apr-Jun;16(2):238-43
pubmed: 22884713
Eur J Endocrinol. 2019 Aug;181(2):R45-R56
pubmed: 31100715
J Clin Endocrinol Metab. 2002 Jun;87(6):2760-3
pubmed: 12050246
Eur J Endocrinol. 2016 Aug;175(2):155-64
pubmed: 27220351
Endocrine. 2014 Nov;47(2):435-48
pubmed: 24853880
J Bone Miner Res. 2014 Mar;29(3):518-30
pubmed: 24443324
Int J Endocrinol. 2019 Nov 03;2019:2102616
pubmed: 31781204
Eur J Endocrinol. 2019 Mar 1;180(3):201-211
pubmed: 30566903
Endokrynol Pol. 2019;70(1):2-18
pubmed: 30843181
J Endocr Soc. 2021 May 15;5(8):bvab090
pubmed: 34195527
J Clin Endocrinol Metab. 1999 Jan;84(1):123-7
pubmed: 9920071
Growth Horm IGF Res. 2014 Feb;24(1):22-8
pubmed: 24382377
Bone. 2017 Nov;104:66-72
pubmed: 28159710
J Transl Med. 2013 Aug 29;11:201
pubmed: 23984630
Horm Metab Res. 2018 Jul;50(7):562-567
pubmed: 29895074
J Clin Endocrinol Metab. 1993 Jun;76(6):1452-7
pubmed: 8501150
Endocr Connect. 2019 Jan 1;8(1):39-49
pubmed: 30640713
Int J Endocrinol. 2015;2015:206853
pubmed: 25873948
J Bone Miner Metab. 2006;24(1):72-8
pubmed: 16369902
J Endocrinol. 2007 Mar;192(3):639-45
pubmed: 17332531
J Clin Endocrinol Metab. 2013 Apr;98(4):1734-41
pubmed: 23482608
Clin Cases Miner Bone Metab. 2011 Sep;8(3):37-43
pubmed: 22461828
Calcif Tissue Int. 1993 Jun;52(6):419-21
pubmed: 8369987
Front Endocrinol (Lausanne). 2020 Jan 14;10:899
pubmed: 32010060